Document Detail

Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis.
MedLine Citation:
PMID:  19164806     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The lipid-derived inflammatory mediators leukotrienes (LTs) are produced during vascular injury. The aim of the present study was to determine the role of LT receptor signaling in the pathophysiology of in-stent stenosis. METHODS AND RESULTS: New Zealand White rabbits were fed 0.3% cholesterol and subjected to angioplasty with balloon dilatation and stent implantation in the right carotid artery. Rabbits treated for 2 weeks with the BLT receptor antagonist BIIL284 (3 mg/kg once daily by oral gavage) displayed a significantly reduced in-stent intimal hyperplasia in carotid arteries compared with vehicle-treated rabbits. In addition, BIIL284 treatment significantly reduced the extracellular matrix metalloproteinase (MMP)-2 and MMP-9 activities in stented arteries. The inhibited MMP-9 activity was correlated with decreased macrophage content in the lesions. The LTB(4)-induced migration of vascular smooth muscle cells was significantly inhibited by transfection with siRNA against MMP-2. Finally, human arteries subjected to ex vivo angioplasty and stent implantation displayed an increased in-stent intimal hyperplasia and higher MMP-2 and -9 activities in the presence of LTB(4). CONCLUSIONS: These results suggest a key role of LT signaling in the extracellular matrix degradation associated with hyperlipidemia and in-stent stenosis. In conclusion, targeting LT receptors may represent a therapeutic strategy in atherosclerosis and interventional cardiology.
Hanna Hlawaty; Marie-Paule Jacob; Liliane Louedec; Didier Letourneur; Charles Brink; Jean-Baptiste Michel; Laurent Feldman; Magnus Bäck
Related Documents :
17696636 - Device-specific resistance to in vivo displacement of stent-grafts implanted with maxim...
15976956 - Reoperations after failure of stent grafting for type b aortic dissection: report of tw...
20549686 - The outcome of pulmonary artery stents following surgical manipulation.
9609156 - A new design of the esophageal wallstent endoprosthesis resistant to distal migration.
25425986 - Pulmonary artery sarcoma mimicking pulmonary embolism.
20072686 - Repeat late instent-stenosis after an interval of four years in the same lesion after b...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-01-22
Journal Detail:
Title:  Arteriosclerosis, thrombosis, and vascular biology     Volume:  29     ISSN:  1524-4636     ISO Abbreviation:  Arterioscler. Thromb. Vasc. Biol.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-03-20     Completed Date:  2009-04-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9505803     Medline TA:  Arterioscler Thromb Vasc Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  518-24     Citation Subset:  IM    
INSERM U698, University of Paris, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Amidines / administration & dosage,  pharmacology*
Angioplasty, Balloon* / adverse effects,  instrumentation
Carbamates / administration & dosage,  pharmacology*
Carotid Artery, Common / drug effects*,  metabolism,  pathology
Carotid Stenosis / etiology,  metabolism,  pathology,  therapy*
Cell Line
Cell Movement / drug effects
Cell Proliferation / drug effects
Cholesterol, Dietary / administration & dosage
Disease Models, Animal
Extracellular Matrix / metabolism*
Leukotriene Antagonists / administration & dosage,  pharmacology*
Leukotriene B4 / metabolism*
Macrophages / drug effects,  metabolism
Mammary Arteries / metabolism,  pathology
Matrix Metalloproteinase 2 / metabolism
Matrix Metalloproteinase 9 / metabolism
Muscle, Smooth, Vascular / drug effects,  metabolism
Myocytes, Smooth Muscle / drug effects,  metabolism
Organ Culture Techniques
RNA Interference
RNA, Small Interfering / metabolism
Recurrence / prevention & control
Time Factors
Reg. No./Substance:
0/Amidines; 0/Carbamates; 0/Cholesterol, Dietary; 0/Leukotriene Antagonists; 0/RNA, Small Interfering; 0/amelubant; 71160-24-2/Leukotriene B4; EC Metalloproteinase 2; EC Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms targeting apolipoprotein B100 to proteasomal degradation: evidence that degradation is in...
Next Document:  The brachial artery remodels to maintain local shear stress despite the presence of cardiovascular r...